Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daphne Moutsoglou

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The American Journal of Gastroenterology|March 28, 2025
Continuing Medical Education Questions: January 2025Daphne Moutsoglou
The American Journal of Gastroenterology|February 4, 2026
Continuing Medical Education Questions: January 2026Daphne Moutsoglou
The American Journal of Gastroenterology|February 13, 2025
Continuing Medical Education Questions: January 2025Daphne Moutsoglou
In Vitro Cellular & Developmental Biology. Animal|July 28, 2009
Osteogenic and adipogenic differentiation potential of an immortalized fibroblast-like cell line derived from porcine peripheral bloodXiuqing Wang, Daphne Moutsoglou
Gut Microbes|March 10, 2025
Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insightsDaphne Moutsoglou, Pavithra Ramakrishnan, Byron P Vaughn
Inflammatory Bowel Diseases|June 23, 2026
Colonoscopic and oral microbiota transplant therapy yield similar stool and neoterminal ileal engraftment profiles in a single-blind pilot randomized trialDaphne Moutsoglou, Christopher Staley, Amanda J Kabage, et al.
Gut Microbes|April 14, 2025
Metagenomic source tracking after microbiota transplant therapySusan L Hoops, Daphne Moutsoglou, Byron P Vaughn, et al.
Inflammatory Bowel Diseases|March 25, 2026
Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalationPavithra Ramakrishnan, James Campbell, Daphne Moutsoglou, et al.
Expert Opinion on Pharmacotherapy|September 18, 2025
Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data studyHussam Almasri, Abdellatif Ismail, Himsikhar Khataniar, et al.
Journal of Immunological Methods|July 23, 2011
Analysis of the effector activity of Ara h 2 and Ara h 6 by selective depletion from a crude peanut extractXueni Chen, Yonghua Zhuang, Qian Wang, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The American Journal of Gastroenterology|March 28, 2025
Continuing Medical Education Questions: January 2025Daphne Moutsoglou
The American Journal of Gastroenterology|February 4, 2026
Continuing Medical Education Questions: January 2026Daphne Moutsoglou
The American Journal of Gastroenterology|February 13, 2025
Continuing Medical Education Questions: January 2025Daphne Moutsoglou
In Vitro Cellular & Developmental Biology. Animal|July 28, 2009
Osteogenic and adipogenic differentiation potential of an immortalized fibroblast-like cell line derived from porcine peripheral bloodXiuqing Wang, Daphne Moutsoglou
Gut Microbes|March 10, 2025
Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insightsDaphne Moutsoglou, Pavithra Ramakrishnan, Byron P Vaughn
Inflammatory Bowel Diseases|June 23, 2026
Colonoscopic and oral microbiota transplant therapy yield similar stool and neoterminal ileal engraftment profiles in a single-blind pilot randomized trialDaphne Moutsoglou, Christopher Staley, Amanda J Kabage, et al.
Gut Microbes|April 14, 2025
Metagenomic source tracking after microbiota transplant therapySusan L Hoops, Daphne Moutsoglou, Byron P Vaughn, et al.
Inflammatory Bowel Diseases|March 25, 2026
Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalationPavithra Ramakrishnan, James Campbell, Daphne Moutsoglou, et al.
Expert Opinion on Pharmacotherapy|September 18, 2025
Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data studyHussam Almasri, Abdellatif Ismail, Himsikhar Khataniar, et al.
Journal of Immunological Methods|July 23, 2011
Analysis of the effector activity of Ara h 2 and Ara h 6 by selective depletion from a crude peanut extractXueni Chen, Yonghua Zhuang, Qian Wang, et al.
Pageof 2